Activity Information

The Rheumatology Review Course 2023 features key updates covering a wide range of rheumatology diseases. This activity contains eight individual video lectures approximately 45 minutes in length, including a Q&A session, and is ideal for anyone needing an introduction to the latest research in rheumatology or simply seeking an activity available at your convenience.

The Review Course is a popular session that takes place annually during ACR Convergence, the ACR’s annual meeting. Topics from the 2023 activity include:

• Inflammatory eye disease diagnosis and treatment
• Transition in juvenile idiopathic arthritis (JIA) care
• Thrombotic microangiopathy
• Relapsing polychondritis
• Radiographic and non-radiographic ankylosing spondylitis
• Systemic sclerosis screening for organ involvement
• Reproductive counseling
• Viral infections and rheumatic diseases

Earn up to 6.00 ABIM MOC points and 6.00 AMA PRA Category 1 Credit(s)™ with a passing score of 70% or higher.

Target Audience

Rheumatologists, physicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

• Summarize up-to-date assessment and management strategies in inflammatory eye disease, polychondritis, and other rheumatic diseases.
• Identify current imaging modalities used to diagnose scleroderma, axial spondyloarthritis and thrombotic microangiopathy.
• Develop skills to facilitate open and accurate discussions about pregnancy prevention and planning.
• Define Juvenile Idiopathic Arthritis (JIA) including its etiology, symptoms, and common treatments.
• Demonstrate understanding of the unique challenges faced by young adults living with JIA.

Registration Fees

ACR/ARP Member: $299
ACR/ARP Potential Member: $499

CME and MOC Information

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The ACR designates this enduring activity for a maximum of 6.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 6.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

By completing this activity you provide the ACR permission to share completion data with the ACCME and the certifying board(s).

Faculty and Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience all financial relationships with ineligible companies any financial or other relationship(s) with a ineligible company including, but not limited to:

1.     Advisor or review panel member

2.     Consultant

3.     Employee

4.     Officer or Board Member

5.     Grant/research support

6.     Speaker/honoraria includes speakers bureau, symposia, and expert witness

7.     Independent contractor

8.     Ownership Interest

9.     Royalties

10.  Intellectual property/patents

11.  Stock options or bond holdings in a for-profit corporation or self-directed pension plan

12.  Other financial or material support

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

Content Bundle Planning/Faculty Team Members

The following Content Bundle Planning/Faculty Team Members have the following financial relationships with ineligible companies to disclose.

• Laura Kopplin, MD - ACELYRIN: Grant/Research Support (Ongoing); Roche: Grant/Research Support (Ongoing)

• Julie Rebecca Sadun, MDAshley M. Cooper, MD - No financial relationships with ineligible companies to disclose

• Thomas Ortel, MD - Sanofi: Consultant (Terminated); Siemens: Grant/Research Support (Ongoing); Stago: Grant/Research Support (Ongoing); Werfen: Consultant (Ongoing), Grant/Research Support (Ongoing)

• Marcela Ferrada, MD - No financial relationships with ineligible companies to disclose

• Alexis Ogdie, MD - AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Celgene: Consultant (Ongoing); CorEvitas: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Gilead: Consultant (Ongoing); GSK: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Takeda: Consultant (Ongoing); UCB: Consultant (Ongoing)

• Francesco Boin, MD - Boehringer-Ingelheim: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, November 25, 2021); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

• Megan Clowse, MD - GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

• Leonard Calabrese, DO - Amgen: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Genentech: Consultant (Terminated); GlaxoSmithKlein(GSK): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Review Team Members

The following team members have no relevant financial relationship(s) with ineligible companies to disclose.

• Adena Batterman, LCSW, MSW
• Maura Daly Iversen, PT, DPT, SD, MPH, FNAP, FAPTA

The following team members have no relevant financial relationship(s) with ineligible companies to disclose.

• Belina Yi, D.O.
• Annelle Reed, MSN, CPNP
• Kai Sun, MD, MS
• Dawn Wahezi, MD, MS
• Rebecca Manno, MD, MHS
• Susan Farrow
• Lawrence Cunningham
• Carlos Ferreira, MA
• Sharon Ross

The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.

• Kaveh Ardalan, MD, MS – Cabaletta Bio, Inc. ¹; Cure JM Foundation⁵
• Susan Shenoi, MBBS, MS, RhMSUS – Pfizer²; Cabaletta Bio, Inc²; Novartis²; Amgen²
• Lesley Ann Saketkoo, MD, MPH - Argenx^1,5; Atyr^1,5; Boehringer Ingelheim^1,5; Horizon^1,5; Janssen^1,5; Kadmon^1,5; Kinevant^1,5; Kyverna^1,5; Mallinckrodt^1,5; Novartis^1,5; UCB^1,5

*All of the relevant financial relationships listed for these individuals have been mitigated.

Corporate Support 

No grant support funded at this time. 

Online Activity Refund Policy

• Requests for cancellations and refunds must be received in writing to education@rheumatology.org within 24 hours of the online activity enrollment date.
• Completed online activities are not eligible for a refund. 
• Refunds will be subject to an administration fee per person and per activity: 15% for members; 30% for potential members.
• Canceled online activities are nontransferable.